Literature DB >> 27174034

Pharmacovigilance activities in ASEAN countries.

Wimon Suwankesawong1, Teerapon Dhippayom2, Wei-Chuen Tan-Koi3,4, Chuenjid Kongkaew5.   

Abstract

PURPOSE: This study aimed to explore the current landscape and identify challenges of pharmacovigilance (PV) among Association of Southeast Asian Nations (ASEAN) countries.
METHODS: This cross-sectional survey collected data from May 2014 to December 2015. Questionnaires seeking to collect information on resources, processes, roles and responsibility, and functions of PV systems were sent to relevant persons in the ASEAN countries. Functions of PV centers were measured using the minimum World Health Organization requirements for a functional national PV system. Performances of PV centers were measured by the following: (1) the indicators related to the average number of individual case safety reports (ICSR); (2) presence of signal detection activities and subsequent action; and (3) contribution to the global vigilance database.
RESULTS: Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, and Vietnam completed the survey. PV systems in four surveyed countries (Indonesia, Malaysia, Singapore, and Thailand) achieved all aspects of the World Health Organization minimum requirement for a functional national PV system; the remaining countries were deemed to have unclear communication strategies and/or no official advisory committee. Average numbers of recent ICSR national returns ranged from 7 to 3817 reports/year/million population; three countries (Malaysia, Singapore, and Thailand) demonstrated good performance in reporting system and reported signal detection activities and subsequent actions. All participating countries had submitted ICSRs to the Uppsala Monitoring Center during the survey period (2013-2015).
CONCLUSIONS: Four participating countries had functional PV systems. PV capacity, functionality, and legislative framework varied depending on local healthcare ecosystem networks. Implementing effective communication strategies and/or technical assistance from the advisory committee are needed to strengthen PV in ASEAN.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ASEAN; Uppsala Monitoring Center; adverse drug reaction; pharmacoepidemiology; pharmacovigilance

Mesh:

Year:  2016        PMID: 27174034     DOI: 10.1002/pds.4023

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  6 in total

1.  A Survey on Pharmacovigilance Activities in ASEAN and Selected Non-ASEAN Countries, and the Use of Quantitative Signal Detection Algorithms.

Authors:  Cheng Leng Chan; Pei San Ang; Shu Chuen Li
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

Review 2.  Overview of Pharmacovigilance System in Vietnam: Lessons Learned in a Resource-Restricted Country.

Authors:  Khac-Dung Nguyen; Phuong-Thuy Nguyen; Hoang-Anh Nguyen; Anne Roussin; Jean-Louis Montastruc; Haleh Bagheri; Sten Olsson
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

3.  Assessment of Knowledge, Attitude, and Practice in Adverse Drug Reaction Reporting of Healthcare Professionals in Vietnam: A Cross-Sectional Study.

Authors:  Hai-Yen Nguyen-Thi; Minh-Thu Do-Tran; Thuyen Lu Ngoc; Thuy-Tram Nguyen-Ngoc; Nguyen Dang Tu Le
Journal:  Hosp Pharm       Date:  2021-09-16

4.  Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study.

Authors:  Una Glamočlija; Biljana Tubić; Martin Kondža; Aleksandar Zolak; Nataša Grubiša
Journal:  Croat Med J       Date:  2018-06-30       Impact factor: 1.351

Review 5.  A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators.

Authors:  Hamza Y Garashi; Douglas T Steinke; Ellen I Schafheutle
Journal:  Ther Innov Regul Sci       Date:  2022-06-03       Impact factor: 1.337

6.  Strengths and Weaknesses of the Pharmacovigilance Systems in Three Arab Countries: A Mixed-Methods Study Using the WHO Pharmacovigilance Indicators.

Authors:  Hamza Garashi; Douglas Steinke; Ellen Schafheutle
Journal:  Int J Environ Res Public Health       Date:  2022-02-22       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.